부산대학교 도서관

This article explores the treatment of acquired hemophilia A (AHA), a condition where individuals without hemophilia develop factor VIII inhibitors. AHA can lead to severe bleeding and is often linked to other medical conditions. The study examines the effectiveness of a plasma-derived factor VIIa and X mixture called Byclot in patients with AHA using a global coagulation assay. The results indicate that Byclot, along with other bypassing agents, showed positive clinical responses in all patients. However, more research is necessary to determine the safety and efficacy of Byclot in treating AHA. The study also analyzed the coagulation potential of pd-FVIIa/FX and rFVIIa in patients with AHA, finding that both treatments improved coagulant potential in whole-blood samples. The study did not find evidence of increased thrombotic risk associated with pd-FVIIa/FX treatment, but it had limitations such as a small sample size and selection bias. Further large-scale clinical studies are needed to evaluate the coagulation potential of pd-FVIIa/FX in patients with AHA. [Extracted from the article]